Abstract
Selection of the month Targeting Toll-like receptor 7 in chronic HBV infection Toll-like receptor (TLR) signaling has been implicated to play a significant role in the context of cytokine-induced ‘curing' of HBV-infected cells. In previous studies, the oral small molecule TLR7 agonist GS-9620 caused a marked HBsAg reduction in chronically HBV-infected chimpanzees. The present study by Menne et al. evaluated GS-9620 in the HBV Woodchuck animal model demonstrating that short duration treatment with the TLR7 agonist was able to induce a sustained antiviral response which is likely due to the induction of local interferon-alpha and natural killer cell and CD8 + T cell responses as well as activation of B cells. A striking reduction in the incidence of hepatocellular carcinoma was also observed in the treated animals. The safety and efficacy of GS-9620 (attaining a functional cure?) will be further developed in a phase II multi-center study in virally-suppressed subjects with chronic hepatitis B (ClinicalTrials.gov NCT02166047).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
